Vincerx Pharma, Inc. (NASDAQ:VINC) Sees Significant Decrease in Short Interest

Vincerx Pharma, Inc. (NASDAQ:VINC) saw a large drop in short interest in January. As of January 15th, there was short interest totalling 55,700 shares, a drop of 98.8% from the December 31st total of 4,710,000 shares. Based on an average daily volume of 7,300,000 shares, the short-interest ratio is currently 0.0 days.

Hedge Funds Weigh In On Vincerx Pharma

A hedge fund recently raised its stake in Vincerx Pharma stock. Marshall Wace LLP boosted its stake in Vincerx Pharma, Inc. (NASDAQ:VINC) by 359.1% in the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 328,533 shares of the company’s stock after buying an additional 256,967 shares during the quarter. Marshall Wace LLP owned approximately 1.11% of Vincerx Pharma worth $266,000 at the end of the most recent quarter. 44.02% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

Separately, Leerink Partners dropped their target price on shares of Vincerx Pharma from $80.00 to $40.00 and set an “outperform” rating on the stock in a report on Tuesday, October 8th.

Vincerx Pharma Trading Up 1.0 %

VINC stock opened at $1.52 on Friday. Vincerx Pharma has a one year low of $1.40 and a one year high of $187.44. The firm has a 50-day moving average of $3.94 and a two-hundred day moving average of $8.79. The firm has a market capitalization of $2.55 million, a PE ratio of -0.07 and a beta of 1.48.

Vincerx Pharma Company Profile

Vincerx Pharma, Inc, a clinical-stage biopharmaceutical company, researches and develops therapies to address unmet medical needs for the treatment of cancer in the United States. It is developing enitociclib, a cyclin-dependent kinase-9 inhibitor that is in Phase 1 clinical trials for treating patients with hematologic malignancies; and VIP236, a small molecule drug conjugate that is in Phase 1 clinical trials to treat solid tumors.